NLRP3炎性小体与骨及关节疾病发生的研究进展

王甲河; 邹淑娟; 谢静; 周陈晨

doi:10.12182/20230560105

NLRP3炎性小体与骨及关节疾病发生的研究进展

doi: 10.12182/20230560105

口腔疾病研究国家重点实验室国家口腔疾病临床医学研究中心四川大学华西口腔医院（成都 610041）

基金项目: 国家自然科学基金项目（No. 81771047、No. 81901040、No. 82171001）资助

详细信息

通讯作者:
E-mail：chenchenzhou5510@scu.edu.cn

计量
- 文章访问数: 24
- HTML全文浏览量: 12
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2022-08-15
- 修回日期: 2023-04-03
- 网络出版日期: 2023-05-20
- 刊出日期: 2023-05-20

Latest Findings on NOD-Like Receptor Family Pyrin Domain Containing Protein 3 Inflammasome and Bone and Articular Diseases

State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

More Information

Corresponding author: E-mail: chenchenzhou5510@scu.edu.cn

摘要

摘要: 炎性小体是固有免疫系统的重要成员，由胞浆内模式识别受体组装，通过影响下游炎症因子释放和激活以及细胞焦亡，在多种炎症性疾病的发生和进展中起到重要作用。目前NLRP3炎性小体已被证明与心血管疾病、代谢异常等密切相关。以骨关节炎、类风湿关节炎等为代表的骨和关节的炎性疾病在人群中发病率高，可导致骨、软骨的器质性破坏，引起疼痛甚至功能障碍，影响生活质量。已有研究提示多种骨和关节炎性疾病发病机制与NLRP3炎性小体相关。针对NLRP3炎性小体的小分子抑制剂显现出一定的治疗前景，但其临床应用可行性仍需进一步探究。本文将对NLRP3炎性小体的构成、作用及其与骨相关疾病的关系进行综述。
- NLRP3炎性小体 /
- 骨稳态 /
- 骨关节炎 /
- 类风湿关节炎
Abstract: Inflammasomes are important components of the innate immune system. They are assembled by cytoplasmic pattern recognition receptors and play a critical role in the pathogenesis and progression of various inflammatory diseases through regulating the release and activation of inflammatory cytokines and inducing cell prytosis. NOD-like receptor family pyrin domain containing protein 3 (NLRP3) inflammasome has been widely studied and has been shown to be closely associated with cardiovascular diseases and metabolic disorders. Bone and joint diseases, such as osteoarthritis and rheumatoid arthritis show high prevalence worldwide and can cause bone and cartilage damage, pain, and dysfunction, adversely affecting the patients' quality of life. The reported findings of some studies indicate that the pathogenesis of various bone and articular diseases is associated with NLRP3 inflammasome. Small molecule antagonists targeting NLRP3 inflammasome have shown considerable therapeutic potentials, but their clinical application still needs further exploration. Herein, we reviewed the composition and function of NLRP3 inflammasome and its association with bone and articular diseases.
- NOD-like receptor family pyrin domain containing protein 3 inflammasome /
- Bone homeostasis /
- Osteoarthritis /
- Rheumatoid arthritis

HTML全文

参考文献(50)

[1]	MARTINON F, BURNS K, TSCHOPP J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell,2002,10(2): 417–426. doi: 10.1016/s1097-2765(02)00599-3
[2]	BROZ P, DIXIT V M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol,2016,16(7): 407–420. doi: 10.1038/nri.2016.58
[3]	RATHINAM V A, FITZGERALD K A. Inflammasome complexes: emerging mechanisms and effector functions. Cell,2016,165(4): 792–800. doi: 10.1016/j.cell.2016.03.046
[4]	PAIK S, KIM J K, SILWAL P, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol,2021,18(5): 1141–1160. doi: 10.1038/s41423-021-00670-3
[5]	Von MOLTKE J, AYRES J S, KOFOED E M, et al. Recognition of bacteria by inflammasomes. Annu Rev Immunol,2013,31: 73–106. doi: 10.1146/annurev-immunol-032712-095944
[6]	SWANSON K V, DENG M, TING J P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol,2019,19(8): 477–489. doi: 10.1038/s41577-019-0165-0
[7]	XUE Y, ENOSI TUIPULOTU D, TAN W H, et al. Emerging activators and regulators of inflammasomes and pyroptosis. Trends Immunol,2019,40(11): 1035–1052. doi: 10.1016/j.it.2019.09.005
[8]	SMOLEN J S, ALETAHA D, BARTON A, et al. Rheumatoid arthritis. Nat Rev Dis Primers,2018,4: 18001. doi: 10.1038/nrdp.2018.1
[9]	KOLLY L, BUSSO N, PALMER G, et al. Expression and function of the NALP3 inflammasome in rheumatoid synovium. Immunology,2010,129(2): 178–185. doi: 10.1111/j.1365-2567.2009.03174.x
[10]	ROSENGREN S, HOFFMAN H M, BUGBEE W, et al. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis,2005,64(5): 708–714. doi: 10.1136/ard.2004.025577
[11]	CHOULAKI C, PAPADAKI G, REPA A, et al. Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Res Ther,2015,17: 257. doi: 10.1186/s13075-015-0775-2
[12]	ZHANG Y, ZHENG Y, LI H. NLRP3 inflammasome plays an important role in the pathogenesis of collagen-induced arthritis. Mediators Inflamm,2016,2016: 9656270. doi: 10.1155/2016/9656270
[13]	GUO C, FU R, WANG S, et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol,2018,194(2): 231–243. doi: 10.1111/cei.13167
[14]	DONG X, ZHENG Z, LIN P, et al. ACPAs promote IL-1beta production in rheumatoid arthritis by activating the NLRP3 inflammasome. Cell Mol Immunol,2020,17(3): 261–271. doi: 10.1038/s41423-019-0201-9
[15]	MATMATI M, JACQUES P, MAELFAIT J, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet,2011,43(9): 908–912. doi: 10.1038/ng.874
[16]	VANDE WALLE L, Van OPDENBOSCH N, JACQUES P, et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature,2014,512(7512): 69–73. doi: 10.1038/nature13322
[17]	LAM I K Y, CHOW J X, LAU C S, et al. MicroRNA-mediated immune regulation in rheumatic diseases. Cancer Lett,2018,431: 201–212. doi: 10.1016/j.canlet.2018.05.044
[18]	LI X F, SHEN W W, SUN Y Y, et al. MicroRNA-20a negatively regulates expression of NLRP3-inflammasome by targeting TXNIP in adjuvant-induced arthritis fibroblast-like synoviocytes. Joint Bone Spine,2016,83(6): 695–700. doi: 10.1016/j.jbspin.2015.10.007
[19]	HUANG Y, LU D, MA W, et al. miR-223 in exosomes from bone marrow mesenchymal stem cells ameliorates rheumatoid arthritis via downregulation of NLRP3 expression in macrophages. Mol Immunol,2022,143: 68–76. doi: 10.1016/j.molimm.2022.01.002
[20]	LI Y, ZHENG J Y, LIU J Q, et al. Succinate/NLRP3 inflammasome induces synovial fibroblast activation: therapeutical effects of clematichinenoside AR on arthritis. Front Immunol,2016,7: 532. doi: 10.3389/fimmu.2016.00532
[21]	HONG Z, ZHANG X, ZHANG T, et al. The ROS/GRK2/HIF-1alpha/NLRP3 pathway mediates pyroptosis of fibroblast-like synoviocytes and the regulation of monomer derivatives of paeoniflorin. Oxid Med Cell Longev,2022,2022: 4566851. doi: 10.1155/2022/4566851
[22]	HAN X, LIN D, HUANG W, et al. Mechanism of NLRP3 inflammasome intervention for synovitis in knee osteoarthritis: a review of TCM intervention. Front Genet,2023,14: 1159167. doi: 10.3389/fgene.2023.1159167
[23]	WOJDASIEWICZ P, PONIATOWSKI L A, SZUKIEWICZ D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm,2014,2014: 561459. doi: 10.1155/2014/561459
[24]	DERFUS B A, KURIAN J B, BUTLER J J, et al. The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol,2002,29(3): 570–574.
[25]	PAZAR B, EA H K, NARAYAN S, et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1beta secretion through the NLRP3 inflammasome in vitro. J Immunol,2011,186(4): 2495–2502. doi: 10.4049/jimmunol.1001284
[26]	DENOBLE A E, HUFFMAN K M, STABLER T V, et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A,2011,108(5): 2088–2093. doi: 10.1073/pnas.1012743108
[27]	MARCHETTI C, SWARTZWELTER B, KOENDERS M I, et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther,2018,20(1): 169. doi: 10.1186/s13075-018-1664-2
[28]	CHENG F, YAN F F, LIU Y P, et al. Dexmedetomidine inhibits the NF-kappaB pathway and NLRP3 inflammasome to attenuate papain-induced osteoarthritis in rats. Pharm Biol,2019,57(1): 649–659. doi: 10.1080/13880209.2019.1651874
[29]	STAROBOVA H, NADAR E I, VETTER I. The NLRP3 Inflammasome: Role and Therapeutic Potential in Pain Treatment. Front Physiol,2020,11: 1016. doi: 10.3389/fphys.2020.01016
[30]	SHAO M, LV D, ZHOU K, et al. Senkyunolide A inhibits the progression of osteoarthritis by inhibiting the NLRP3 signalling pathway. Pharm Biol,2022,60(1): 535–542. doi: 10.1080/13880209.2022.2042327
[31]	LI W, WANG Y, TANG Y, et al. Quercetin alleviates osteoarthritis progression in rats by suppressing inflammation and apoptosis via inhibition of IRAK1/NLRP3 signaling. J Inflamm Res,2021,14: 3393–3403. doi: 10.2147/JIR.S311924
[32]	HE M, LU B, OPOKU M, et al. Metformin prevents or delays the development and progression of osteoarthritis: new insight and mechanism of action. Cells,2022,11(19): 3012. doi: 10.3390/cells11193012
[33]	LORDEN G, SANJUAN-GARCIA I, De PABLO N, et al. Lipin-2 regulates NLRP3 inflammasome by affecting P2X7 receptor activation. J Exp Med,2017,214(2): 511–528. doi: 10.1084/jem.20161452
[34]	HOFMANN S R, KUBASCH A S, IOANNIDIS C, et al. Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1beta expression and release. Clin Immunol,2015,161(2): 300–307. doi: 10.1016/j.clim.2015.09.013
[35]	BRANDT D, SOHR E, PABLIK J, et al. CD14(+) monocytes contribute to inflammation in chronic nonbacterial osteomyelitis (CNO) through increased NLRP3 inflammasome expression. Clin Immunol,2018,196: 77–84. doi: 10.1016/j.clim.2018.04.011
[36]	SCIANARO R, INSALACO A, BRACCI LAUDIERO L, et al. Deregulation of the IL-1beta axis in chronic recurrent multifocal osteomyelitis. Pediatr Rheumatol Online J,2014,12: 30. doi: 10.1186/1546-0096-12-30
[37]	DASARI T K, GEIGER R, KARKI R, et al. The nonreceptor tyrosine kinase SYK drives caspase-8/NLRP3 inflammasome-mediated autoinflammatory osteomyelitis. J Biol Chem,2020,295(11): 3394–3400. doi: 10.1074/jbc.RA119.010623
[38]	XUE F, SHU R, XIE Y. The expression of NLRP3, NLRP1 and AIM2 in the gingival tissue of periodontitis patients: RT-PCR study and immunohistochemistry. Arch Oral Biol,2015,60(6): 948–958. doi: 10.1016/j.archoralbio.2015.03.005
[39]	SURLIN P, LAZAR L, SINCAR C, et al. NLRP3 inflammasome expression in gingival crevicular fluid of patients with periodontitis and chronic hepatitis C. Mediators Inflamm,2021,2021: 6917919. doi: 10.1155/2021/6917919
[40]	ISOLA G, POLIZZI A, SANTONOCITO S, et al. Periodontitis activates the NLRP3 inflammasome in serum and saliva. J Periodontol,2022,93(1): 135–145. doi: 10.1002/JPER.21-0049
[41]	HIENZ S A, PALIWAL S, IVANOVSKI S. Mechanisms of Bone Resorption in Periodontitis. J Immunol Res,2015,2015: 615486. doi: 10.1155/2015/615486
[42]	MURAKAMI T, TAKAHATA Y, HATA K, et al. Role of interleukin-1 and inflammasomes in oral disease. J Oral Biosci,2020,62(3): 242–248. doi: 10.1016/j.job.2020.07.003
[43]	MONTENEGRO RAUDALES J L, YOSHIMURA A, SM Z, et al. Dental calculus stimulates interleukin-1beta secretion by activating NLRP3 Inflammasome in human and mouse phagocytes. PLoS One,2016,11(9): e0162865. doi: 10.1371/journal.pone.0162865
[44]	YAMAGUCHI Y, KURITA-OCHIAI T, KOBAYASHI R, et al. Regulation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated periodontal disease. Inflamm Res,2017,66(1): 59–65. doi: 10.1007/s00011-016-0992-4
[45]	LIAN D, DAI L, XIE Z, et al. Periodontal ligament fibroblasts migration injury via ROS/TXNIP/Nlrp3 inflammasome pathway with Porphyromonas gingivalis lipopolysaccharide. Mol Immunol,2018,103: 209–219. doi: 10.1016/j.molimm.2018.10.001
[46]	ZHAO P, LIU J, PAN C, et al. NLRP3 inflammasome is required for apoptosis of Aggregatibacter actinomycetemcomitans-infected human osteoblastic MG63 cells. Acta Histochem,2014,116(7): 1119–1124. doi: 10.1016/j.acthis.2014.05.008
[47]	KELK P, MOGHBEL N S, HIRSCHFELD J, et al. Aggregatibacter actinomycetemcomitans leukotoxin activates the NLRP3 inflammasome and cell-to-cell communication. Pathogens,2022,11(2): 159. doi: 10.3390/pathogens11020159
[48]	CHEN Y, YANG Q, LV C, et al. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation. Cell Prolif,2021,54(2): e12973. doi: 10.1111/cpr.12973
[49]	KAWAHARA Y, KANEKO T, YOSHINAGA Y, et al. Effects of sulfonylureas on periodontopathic bacteria-induced inflammation. J Dent Res,2020,99(7): 830–838. doi: 10.1177/0022034520913250
[50]	CHAUHAN D, VANDE WALLE L, LAMKANFI M. Therapeutic modulation of inflammasome pathways. Immunol Rev,2020,297(1): 123–138. doi: 10.1111/imr.12908